AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34000072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase to carboxyhemoglobin ratio
Number of subjects: 0
Study 34000072 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34000073 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34000076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 513
Study 34000211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth visits
Number of subjects: 162
Study 34000211 — intervention group
Group type: COMPARATOR
Intervention: No telehealth visits
Number of subjects: 162
Study 34000235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption during ECMO
Number of subjects: 0
Study 34000246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks for up to 93 weeks
Number of subjects: 84
Study 34000246 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 84
Study 34000620 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 μg/kg/day sargramostim
Number of subjects: 5
Study 34000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent without mitomycin C (MMC)
Number of subjects: 177
Study 34000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone Xen45 gel stent with mitomycin C (MMC)
Number of subjects: 177
Study 34000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Xen45 gel stent combined with cataract surgery without mitomycin C (MMC)
Number of subjects: 177
Study 34000747 — intervention group
Group type: EXPERIMENTAL
Intervention: Xen45 gel stent combined with cataract surgery with mitomycin C (MMC)
Number of subjects: 177
Study 34000994 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried highbush blueberry powder (BBP), 50 g daily for 8 weeks
Number of subjects: 49
Study 34000994 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 49
Study 34001010 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, administered in 4 doses as a short course of immunotherapy.
Number of subjects: 80
Study 34001055 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey of Life (JoL) intervention
Number of subjects: 600
Study 34001055 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control
Number of subjects: 600
Study 34001067 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month vocational rehabilitation programme
Number of subjects: 95
Study 34001113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-admission to psychiatric inpatient treatment
Number of subjects: 0
Study 34001145 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive screening for HCV antibodies (Ab) by finger prick and facilitated referral to a specialist.
Number of subjects: 425
Study 34001145 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors assessment through a face-to-face questionnaire.
Number of subjects: 425
Study 34001523 — intervention group
Group type: EXPERIMENTAL
Intervention: NKTR-255
Number of subjects: 0
Study 34001523 — intervention group
Group type: COMPARATOR
Intervention: rhIL-15
Number of subjects: 0
Study 34001523 — intervention group
Group type: COMPARATOR
Intervention: precomplexed cytokines (rhIL-15/IL-15Rα and rhIL-15 N72D/IL-15Rα Fc)
Number of subjects: 0
Study 34001647 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab therapy
Number of subjects: 285
Study 34001692 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual IL-17A and IL-17F neutralization
Number of subjects: 0
Study 34001692 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-17A therapy
Number of subjects: 0
Study 34001692 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17F and IL-17C
Number of subjects: 0
Study 34001692 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17D
Number of subjects: 0
Study 34001709 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port robotic transanal minimally invasive surgery
Number of subjects: 26
Study 34001710 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Port Robotic Transanal Total Mesorectal Excision
Number of subjects: 0
Study 34001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens-assisted crosslinking (CA-CXL) with iso-osmolar riboflavin and ultraviolet-A irradiation for 30 min (fluence, 3 mW/cm2)
Number of subjects: 30
Study 34001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens-assisted crosslinking (CA-CXL)
Number of subjects: 30
Study 34001758 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement at the dependent arm
Number of subjects: 42
Study 34001758 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure (NIBP) measurement at the nondependent arm
Number of subjects: 42
Study 34001758 — intervention group
Group type: COMPARATOR
Intervention: Invasive blood pressure (IBP) measurement
Number of subjects: 42
Study 34001758 — intervention group
Group type: EXPERIMENTAL
Intervention: NIBP measurement at both arms
Number of subjects: 42
Study 34001808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium dietary intervention
Number of subjects: 106
Study 34001808 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium dietary intervention
Number of subjects: 106
Study 34002039 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight fluctuations in COVID-19 survivors with overweight/obesity
Number of subjects: 185
Study 34002039 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal adiposity in COVID-19 survivors with overweight/obesity
Number of subjects: 185
Study 34002356 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg orally
Number of subjects: 24
Study 34002866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological and non-pharmacological interventions
Number of subjects: 10990
Study 34002866 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no intervention
Number of subjects: 10990
Study 34003074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5FU, and afatinib every 21 days followed by afatinib maintenance monotherapy
Number of subjects: 55
Study 34003074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5FU, and afatinib
Number of subjects: 55
Study 34003409 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NCT)
Number of subjects: 32
Study 34003586 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs
Number of subjects: 0
Study 34003586 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-dependent mechanism
Number of subjects: 0
Study 34003670 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter electrosurgical aortic leaflet laceration (BASILICA)
Number of subjects: 30
Study 34004383 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic discontinuation
Number of subjects: 0
Study 34004383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34004576 — intervention group
Group type: EXPERIMENTAL
Intervention: Small molecules proposed to reverse the gene expression signature of OS based on a meta-analysis of gene expression.
Number of subjects: 93
Study 34004576 — intervention group
Group type: COMPARATOR
Intervention: Validation group of 82 OS samples
Number of subjects: 93
Study 34006024 — intervention group
Group type: EXPERIMENTAL
Intervention: E-health intervention with integrated and stepped psychosocial services
Number of subjects: 338
Study 34006024 — intervention group
Group type: COMPARATOR
Intervention: Usual psychosocial care
Number of subjects: 338
Study 34006027 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment programme for eating disorders including hospitalisation, day hospital, and outpatient settings.
Number of subjects: 0
Study 34006037 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Guard (dual-AI LLIN with pyriproxyfen and alpha-cypermethrin)
Number of subjects: 0
Study 34006037 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor G2 (dual-AI LLIN with chlorfenapyr and alpha-cypermethrin)
Number of subjects: 0
Study 34006037 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset Plus (dual-AI LLIN with piperonyl butoxide and permethrin)
Number of subjects: 0
Study 34006037 — intervention group
Group type: COMPARATOR
Intervention: Interceptor LN (standard LLIN with alpha-cypermethrin)
Number of subjects: 0
Study 34006282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic reinforcement mesh (Group M)
Number of subjects: 187
Study 34006282 — intervention group
Group type: COMPARATOR
Intervention: Suture (Group S)
Number of subjects: 187
Study 34006291 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy based on actionable genetic alterations (AGAs)
Number of subjects: 550
Study 34006291 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched therapy
Number of subjects: 550
Study 34006291 — intervention group
Group type: COMPARATOR
Intervention: t-NGS/aCGH
Number of subjects: 550
Study 34006291 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive molecular profiling
Number of subjects: 550
Study 34006315 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stress-related exhaustion disorder
Number of subjects: 161
Study 34006315 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 161
Study 34006499 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily, orally, in combination with durvalumab 1500 mg, intravenously, every 28 days.
Number of subjects: 16
Study 34006504 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Atrial Appendage (RAA) expansion index
Number of subjects: 60
Study 34006504 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial (LA) expansion index
Number of subjects: 60
Study 34006504 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) presence
Number of subjects: 60
Study 34006504 — intervention group
Group type: COMPARATOR
Intervention: Right Atrial (RA) expansion index with RLS
Number of subjects: 60
Study 34006504 — intervention group
Group type: COMPARATOR
Intervention: Right Atrial Appendage (RAA) expansion index with RLS
Number of subjects: 60
Study 34006504 — intervention group
Group type: COMPARATOR
Intervention: Left Atrial (LA) expansion index with RLS
Number of subjects: 60
Study 34006504 — intervention group
Group type: COMPARATOR
Intervention: Left Atrial Appendage (LAA) expansion index with RLS
Number of subjects: 60
Study 34006504 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary to systemic blood flow ratio (Qp/Qs) with RLS
Number of subjects: 60
Study 34007002 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine (svmPoly)
Number of subjects: 40
Study 34007002 — intervention group
Group type: COMPARATOR
Intervention: Conventional PA biomarkers (plasma total 2-methylcitrate and propionylcarnitine)
Number of subjects: 40
Study 34007002 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbiased dimensional reduction using svmPoly
Number of subjects: 40
Study 34007050 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK inhibitor selumetinib
Number of subjects: 0
Study 34007050 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 34007050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34007150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection (IAI), 5 monthly injections followed by ProReNata regimen
Number of subjects: 46
Study 34007150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept injection (IAI)
Number of subjects: 46
Study 34007803 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) coagulation tests (thromboelastography and Sonoclot)
Number of subjects: 142
Study 34007803 — intervention group
Group type: COMPARATOR
Intervention: Standard coagulation tests (SCTs)
Number of subjects: 142
Study 34007845 — intervention group
Group type: EXPERIMENTAL
Intervention: R-HIIT
Number of subjects: 0
Study 34007899 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (5-week supply mailed free-of-charge)
Number of subjects: 800
Study 34008097 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME)
Number of subjects: 28
Study 34008097 — intervention group
Group type: COMPARATOR
Intervention: Partial mesorectal excision (PME)
Number of subjects: 28
Study 34008097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TME and PME
Number of subjects: 28
Study 34008163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimini population
Number of subjects: 662
Study 34008342 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram for 8 weeks followed by escitalopram monotherapy for responders or adjunctive aripiprazole for non-responders for an additional 8 weeks.
Number of subjects: 159
Study 34008342 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive aripiprazole for non-responders after initial treatment with escitalopram.
Number of subjects: 159
Study 34008784 — intervention group
Group type: EXPERIMENTAL
Intervention: FG < p10 group
Number of subjects: 349
Study 34008784 — intervention group
Group type: COMPARATOR
Intervention: Normal fasting glucose group
Number of subjects: 349
Study 34009010 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34009072 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition focused quality improvement program (QIP)
Number of subjects: 600
Study 34009141 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate treatment
Number of subjects: 0
Study 34009141 — intervention group
Group type: EXPERIMENTAL
Intervention: Veverimer (a novel nonabsorbable polymer)
Number of subjects: 0
Study 34009141 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-lowering interventions
Number of subjects: 0
Study 34009140 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for uterine sarcoma in early stages
Number of subjects: 0
Study 34009140 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical approaches and fertility-sparing surgery
Number of subjects: 0
Study 34009140 — intervention group
Group type: EXPERIMENTAL
Intervention: New targeted therapies (e.g., DNA repair machinery, immune therapies, TGF-beta pathway, mTOR inhibitors, anti-angiogenics)
Number of subjects: 0
Study 34009140 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for uterine sarcoma
Number of subjects: 0
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) imaging
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy (URS)
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical nephroureterectomy
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental resection
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tumour resection
Number of subjects: 2380
Study 34009177 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney sparing surgery
Number of subjects: 2380
Study 34009243 — intervention group
Group type: COMPARATOR
Intervention: Resting-state functional connectivity (rsFC) in XXY males
Number of subjects: 75
Study 34009243 — intervention group
Group type: COMPARATOR
Intervention: DLPFC-precuneus rsFC
Number of subjects: 75
Study 34009243 — intervention group
Group type: COMPARATOR
Intervention: Functional overconnectivity
Number of subjects: 75
Study 34009391 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Integrative Health (CIH) therapies including chiropractic, acupuncture, multimodal individualized interventions/programs, physiotherapy, and anthroposophic medicine therapy
Number of subjects: 8464
Study 34009501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
Number of subjects: 30
Study 34009501 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks.
Number of subjects: 30
Study 34009837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA) for pulmonary vein isolation (PVI)
Number of subjects: 249
Study 34009877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs)
Number of subjects: 2557
Study 34009877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs) in adult patients
Number of subjects: 2557
Study 34009877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring do-not-do recommendations (DNDs) in pediatric patients
Number of subjects: 2557
Study 34010223 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated LDL cholesterol levels
Number of subjects: 0
Study 34010223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower LDL cholesterol levels
Number of subjects: 0
Study 34010223 — intervention group
Group type: COMPARATOR
Intervention: Statins (clinical trials)
Number of subjects: 0
Study 34011176 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Food Insecurity (FI)
Number of subjects: 1247
Study 34011176 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 1247
Study 34011176 — intervention group
Group type: COMPARATOR
Intervention: HIV negative status
Number of subjects: 1247
Study 34011199 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based intervention
Number of subjects: 0
Study 34011199 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34011305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin reference interval for children 2-36 months of age
Number of subjects: 2106
Study 34011305 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Corpuscular Volume (MCV) reference interval for children 2-7 months of age
Number of subjects: 2106
Study 34011410 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions (EBIs) including improvement of patient education materials, provision of provider education, enhancement of electronic health record (EHR) systems, development of clinic screening protocols, and implementation of community CRC awareness events.
Number of subjects: 0
Study 34011410 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinics' individually tailored multilevel interventions (MLIs) addressing barriers at patient, provider, clinic, and community levels.
Number of subjects: 0
Study 34011535 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Number of subjects: 32
Study 34011535 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic profiling (targeted next-generation sequencing of 425 cancer-related genes)
Number of subjects: 32
Study 34011601 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation (TeleNS)
Number of subjects: 100
Study 34011601 — intervention group
Group type: COMPARATOR
Intervention: In-person examination
Number of subjects: 100
Study 34011634 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-prediction model for pediatric HA-VTE
Number of subjects: 111352
Study 34011835 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Resting
Number of subjects: 0
Study 34011835 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial Revascularization
Number of subjects: 0
Study 34011995 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 blockade treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study 34011995 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34012367 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 8
Study 34012418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive training for upper extremity function, details on dosage and duration not available
Number of subjects: 0
Study 34012418 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34012620 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal endomicroscopy
Number of subjects: 36
Study 34012780 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscopy (FB) examination
Number of subjects: 615
Study 34012780 — intervention group
Group type: COMPARATOR
Intervention: Surgical intervention (thoracoscopic or open surgery)
Number of subjects: 615
Study 34012920 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg per day for a cycle of 28 days)
Number of subjects: 32
Study 34013092 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI pathway
Number of subjects: 11070
Study 34013094 — intervention group
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Number of subjects: 30
Study 34013094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34013139 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal negative pressure (ENP) therapy via polyurethane foam (EsoSponge)
Number of subjects: 40
Study 34013143 — intervention group
Group type: EXPERIMENTAL
Intervention: ReHub telerehabilitation system
Number of subjects: 52
Study 34013143 — intervention group
Group type: COMPARATOR
Intervention: Fast Track recovery protocol (control group)
Number of subjects: 52
Study 34013182 — intervention group
Group type: EXPERIMENTAL
Intervention: VCX stent grafts underdilated to 8 mm
Number of subjects: 114
Study 34013182 — intervention group
Group type: COMPARATOR
Intervention: VTS stent grafts underdilated to 8 mm
Number of subjects: 114
Study 34013252 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100
Study 34013252 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 100
Study 34013254 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34013257 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34013386 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese TTS patients
Number of subjects: 2173
Study 34013386 — intervention group
Group type: COMPARATOR
Intervention: European TTS patients
Number of subjects: 2173
Study 34013498 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients without complications
Number of subjects: 545
Study 34013498 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes zoster (HZ) patients with postherpetic neuralgia (PHN)
Number of subjects: 545